1.Pergola C, Gaboriaud-Kolar N, Jestädt N, König S, Kritsanida M, Schaible AM, Li H, Garscha U, Weinigel C, Barz D, Albring KF, Huber O, Skaltsounis AL, Werz O.. (2014) Indirubin core structure of glycogen synthase kinase-3 inhibitors as novel chemotype for intervention with 5-lipoxygenase., 57 (9):[PMID:24697244][10.1021/jm401740w]
2.Evdokimov NM, Magedov IV, McBrayer D, Kornienko A.. (2016) Isatin derivatives with activity against apoptosis-resistant cancer cells., 26 (6):[PMID:26883150][10.1016/j.bmcl.2016.02.015]
3.Gaboriaud-Kolar N, Myrianthopoulos V, Vougogiannopoulou K, Gerolymatos P, Horne DA, Jove R, Mikros E, Nam S, Skaltsounis AL.. (2016) Natural-Based Indirubins Display Potent Cytotoxicity toward Wild-Type and T315I-Resistant Leukemia Cell Lines., 79 (10):[PMID:27726390][10.1021/acs.jnatprod.6b00285]
4.Ichimaru Y, Fujii T, Saito H, Sano M, Uchiyama T, Miyairi S.. (2017) 5-Bromoindirubin 3'-(O-oxiran-2-ylmethyl)oxime: A long-acting anticancer agent and a suicide inhibitor for epoxide hydrolase., 25 (17):[PMID:28743492][10.1016/j.bmc.2017.07.009]
5.Wang H, Wang Z, Wei C, Wang J, Xu Y, Bai G, Yao Q, Zhang L, Chen Y.. (2021) Anticancer potential of indirubins in medicinal chemistry: Biological activity, structural modification, and structure-activity relationship., 223 [PMID:34161865][10.1016/j.ejmech.2021.113652]
6.Li H, Mattingly AE, Smith RD, Melander RJ, Ernst RK, Melander C.. (2023) 6-Bromoindirubin-3'-oxime derivatives are highly active colistin adjuvants against Klebsiella pneumoniae., 14 (2.0):[PMID:36846374][10.1039/d2md00370h]
